Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra L Close

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Fundamental & Clinical Pharmacology|September 2, 2011
Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant?Sandra L Close
Drug Metabolism and Drug Interactions|August 9, 2011
Clopidogrel pharmacogenetics: metabolism and drug interactionsSandra L Close
Cardiovascular Therapeutics|September 3, 2011
TRITON and beyond: new insights into the profile of prasugrelJoseph A Jakubowski, Jeffrey S Riesmeyer, Sandra L Close, et al.
Journal of Clinical Laboratory Analysis|May 6, 2026
Assessment of Potential Sources of Variability on the Analytical Performance of a Circulating Tumor DNA Minimal Residual Disease Test for B-Cell LymphomasNina Klimova, Alanna Roff, Justine McCutcheon, et al.
Lancet (London, England)|August 31, 2010
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysisJessica L Mega, Sandra L Close, Stephen D Wiviott, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 24, 2009
A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD)Nicolas Ramoz, Claudette Boni, Anncatherine M Downing, et al.
European Heart Journal|May 12, 2009
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery diseaseChristoph Varenhorst, Stefan James, David Erlinge, et al.
British Journal of Clinical Pharmacology|June 22, 2011
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variantsRonan P Kelly, Sandra L Close, Nagy A Farid, et al.
The New England Journal of Medicine|December 25, 2008
Cytochrome p-450 polymorphisms and response to clopidogrelJessica L Mega, Sandra L Close, Stephen D Wiviott, et al.
Circulation|May 6, 2009
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomesJessica L Mega, Sandra L Close, Stephen D Wiviott, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Fundamental & Clinical Pharmacology|September 2, 2011
Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant?Sandra L Close
Drug Metabolism and Drug Interactions|August 9, 2011
Clopidogrel pharmacogenetics: metabolism and drug interactionsSandra L Close
Cardiovascular Therapeutics|September 3, 2011
TRITON and beyond: new insights into the profile of prasugrelJoseph A Jakubowski, Jeffrey S Riesmeyer, Sandra L Close, et al.
Journal of Clinical Laboratory Analysis|May 6, 2026
Assessment of Potential Sources of Variability on the Analytical Performance of a Circulating Tumor DNA Minimal Residual Disease Test for B-Cell LymphomasNina Klimova, Alanna Roff, Justine McCutcheon, et al.
Lancet (London, England)|August 31, 2010
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysisJessica L Mega, Sandra L Close, Stephen D Wiviott, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 24, 2009
A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD)Nicolas Ramoz, Claudette Boni, Anncatherine M Downing, et al.
European Heart Journal|May 12, 2009
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery diseaseChristoph Varenhorst, Stefan James, David Erlinge, et al.
British Journal of Clinical Pharmacology|June 22, 2011
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variantsRonan P Kelly, Sandra L Close, Nagy A Farid, et al.
The New England Journal of Medicine|December 25, 2008
Cytochrome p-450 polymorphisms and response to clopidogrelJessica L Mega, Sandra L Close, Stephen D Wiviott, et al.
Circulation|May 6, 2009
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomesJessica L Mega, Sandra L Close, Stephen D Wiviott, et al.
Pageof 2